Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

A new study has found that adults with depression who start treatment with newer antipsychotic medications may face a higher ...

Sooma announced that it received FDA investigational device exemption (IDE) for its transcranial direct current stimulation ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...